Otsuka Pharma, Proteus Digital Join To Develop, Sell New Type Of Drugs
This article was originally published in PharmAsia News
Otsuka Pharmaceutical and U.S. drug maker Proteus Digital Health have agreed to joint development and marketing of what they called a new category of medicines.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.